The increasingly popular class of GLP-1 receptor agonist and GIP dual medications, like tirzepatide, semaglutide, and the newly introduced retatrutide, represent promising progress in diabetes treatment https://mots-c-peptide315741.blogger-ai.com/64070/semaglutide-the-comparative-review